CRSP Company, also known as CRISPR Therapeutics, is a biotechnology firm specializing in gene editing technologies. They leverage CRISPR/Cas9 technology to develop transformative gene-based medicines for serious diseases, including cancer, diabetes, and genetic disorders. Founded in 2013 by Emmanuelle Charpentier and Rodger Novak, the company has made significant strides in clinical trials and partnerships with major pharmaceutical companies. CRISPR Therapeutics generates revenue through collaborations, licensing agreements, and the development of proprietary therapies. Their pioneering work in gene editing positions them at the forefront of medical innovation.